IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells

Growth Hormone and IGF Research

Volumn 9, Issue 5, 1999, Pages 280-289

  Jackson, James G ^a   Yee, Douglas ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; Insulin like growth factors; Insulin receptor substrate; Signal transduction

Indexed keywords

ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0032696065     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.1999.0113     Document Type: Article

References (27)

1. LeRoith D. Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Eng J Med. 336:1997;633-640.
2. White M. F. The IRS-signaling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 182:1998;3-11.
3. Waters S. B., Pessin J. E. Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Tr Cell Biol. 6:1996;1-4.
4. Araki E., Lipes M. A., Patti M. E., Bruning J. C., Haag B., Johnson R. S., Kahn C. R. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 372:1994;186-190.
5. Withers D. J., Gutierrez J. S., Towery H., Burks D. J., Ren J. M., Previs S., Zhang Y., Bernal D., Pons S., Shulman G. I., Bonner-Weir S., White M. F. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:1998;900-904.
6. Sharma P. M., Egawa K., Gustafson T. A., Martin J. L., Olefsky J. M. Adenovirus-mediated overexpression of IRS-1 interacting domains abolishes insulin-stimulated mitogenesis without affecting glucose transport in 3T3-L1 adipocytes. Mol Cell Biol. 17:1997;7386-7397.
7. Rother K. I., Imai Y., Caruso M., Beguinot F., Formisano P., Accili D. Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem. 273:1998;17491-17497.
8. Jackson J. G., White M. F., Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. 273:1998;9994-10003.
9. Surmacz E., Burgaud J-L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res. 1:1995;1429-1436.
10. Wang L-M., Myers M. G. Jr, Sun X-J., Aaronson S. A., White M. F., Pierce J. H. IRS-1: essential for insulin- and IL-4-stimulated mitogensis in hematopoietic cells. Science. 261:1993;1591-1594.
11. Dambrosio C., Keller S. R., Morrione A., Lienhard G. E., Baserga R., Surmacz E. Transforming potential of the insulin receptor substrate 1. Cell Growth Diff. 6:1995;557-562.
12. Myers M. G., Grammer T. C., Wang L. M., Sun X. J., Pierce J. H., Blenis J., White M. F. Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70(S6k) signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. Biol Chem. 269:1994;28783-28789.
13. Bruning J. C., Winnay J., Cheatham B., Kahn C. R. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 17:1997;1513-1521.
14. Reiss K., C D. A., Tu X., Tu C., Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 4:1998;2647-2655.
15. Leonessa F., Green D., Licht T., Wright A., Wingatelegette K., Lippman J., Gottesman M. M., Clarke R. MDA435/LCC6 and MDA435/LCC6(MDR1): ascites models of human breast cancer. Br J Cancer. 73:1996;154-161.
16. Choudhury G. G., Biswas P., Grandaliano G., Fouqueray B., Harvey S. A., Abboud H. E. PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells. Kidney Int. 46:1994;37-47.
17. Twentyman P. R., Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:1987;279-285.
18. Rocchi S., Tartare-Deckert S., Mothe I., Van Obberghen E. Identification by mutation of the tyrosine residues in the insulin receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinase. Endocrinology. 136:1995;5291-5297.
19. Sepp-Lorenzino L., Rosen N., Lebwohl D. E. Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell Growth Diff. 5:1994;1077-1083.
20. Guvakova M. A., Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res. 231:1997;149-162.
21. Daws M. R., Westley B. R., May F. E. B. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. Endocrinology. 137:1996;1177-1186.
22. Dufourny B., Alblas J., van Teeffelen H. A. A. M., van Schaik F. M. A., van der Burg B., Steenbergh P. H., Sussenbach J. S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 272:1997;31163-31171.
23. Lee A. V., Jackson J. G., Gooch J. G., Hilsenbeck S. G., Coronado-Heinsohn E., Osborne C. K., Yee D. Enhancement of the insulin-like growth factor pathway by estrogen in human breast cancer cells. Mol Endocrinol. 13:1999;787-796.
24. Cullen K. J., Yee D., Sly W. S., Perdue J., Hampton B., Lippman M. E., Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 50:1990;48-53.
25. Mothe I., Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem. 271:1996;11222-11227.
26. Myers M. G., Zhang Y. T., Aldaz G. A. I., Grammer T., Glasheen E. M., Yenush L., Wang L. M., Sun X. J., Blenis J., Pierce J. H., White M. F. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites. Mol Cell Biol. 16:1996;4147-4155.
27. Olayioye M. A., Graus-Porta D., Beerli R. R., Rohrer J., Gay B., Hynes N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerzation partner. Mol Cell Biol. 18:1998;5042-5051.